Metabolic considerations of drugs in the treatment of allergic diseases

Bibliography

• van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131(3):646-57
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109(3):410-18
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128(6):1139-50; e4
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Ayuso P, Martinez C, et al. Histamine pharmacogenomics. Pharmacogenomics 2009;10(5):867-83
   PubMed Web of Science ®Google Scholar
• Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 2002;23(5):255-63
   PubMed Web of Science ®Google Scholar
• Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24
   PubMed Web of Science ®Google Scholar
• Tashiro M, Kato M, Miyake M, et al. Dose dependency of brain histamine H(1) receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [11C]doxepin. Hum Psychopharmacol 2009;24(7):540-8
   PubMed Web of Science ®Google Scholar
• van Ruitenbeek P, Vermeeren A, Riedel W. Histamine H1-receptor blockade in humans affects psychomotor performance but not memory. J Psychopharmacol 2008;22(6):663-72
   PubMed Web of Science ®Google Scholar
• Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987;59(6 Pt 2):31-4
   PubMedGoogle Scholar
• Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985;10(6):477-97
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Bouayad A, Drolet B, et al. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998;26(6):536-9
   PubMed Web of Science ®Google Scholar
• PharmGkb. The pharmacogenomics knowledgebase. 2013. Available from: http://www.pharmgkb.org [Last accessed 31 May 2013]
   Google Scholar
• DrugBank. Open data drug & drug target database. 2013. Available from: http://www.drugbank.ca/ [Last accessed 31 May 2013]
   Google Scholar
• Yasuda SU, Zannikos P, Young AE, et al. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002;53(5):519-25
   PubMed Web of Science ®Google Scholar
• Saruwatari J, Matsunaga M, Ikeda K, et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006;62(12):995-1001
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002;300(1):298-304
   PubMed Web of Science ®Google Scholar
• Kang W, Liu KH, Ryu JY, Shin JG. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813(1-2):75-80
   PubMed Web of Science ®Google Scholar
• Julien-Larose C, Guerret M, Lavene D, Kiechel JR. Quantification of ketotifen and its metabolites in human plasma by gas chromatography mass spectrometry. Biomed Mass Spectrom 1983;10(3):136-42
   PubMedGoogle Scholar
• Howarth PH. A review of the tolerability and safety of levocabastine eye drops and nasal spray. Implications for patient management. Mediators Inflamm 1995;4(7):S26-30
   PubMedGoogle Scholar
• Ghosal A, Gupta S, Ramanathan R, et al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett 2009;3(3):162-70
   PubMedGoogle Scholar
• Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996;51(2):165-72
   PubMed Web of Science ®Google Scholar
• Yin OQ, Shi XJ, Tomlinson B, Chow MS. Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos 2005;33(9):1283-7
   PubMed Web of Science ®Google Scholar
• Li C, Lee MY, Choi JS. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie 2010;65(7):510-14
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 2004;44(11):1252-9
   PubMed Web of Science ®Google Scholar
• Kajita J, Inano K, Fuse E, et al. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos 2002;30(12):1504-11
   PubMed Web of Science ®Google Scholar
• Nickels AS, Dimov V, Wolf R. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol 2011;7(12):1593-9
   PubMed Web of Science ®Google Scholar
• Srinivas NR. Unsuspected polymorphic metabolism of rupatadine via its primary metabolite, desloratadine. Prim Care Respir J 2009;18(2):118-19
   PubMedGoogle Scholar
• Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J 2009;18(2):57-68
   PubMedGoogle Scholar
• Amsterdam A, Tajima K, Sasson R. Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. Biochem Pharmacol 2002;64(5-6):843-50
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem 2011;286(38):32899-905
   PubMed Web of Science ®Google Scholar
• Roberts JK, Moore CD, Ward RM, et al. Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes. J Pharmacol Exp Ther 2013;345(2):308-16
   PubMed Web of Science ®Google Scholar
• Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos 2013;41(2):379-89
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Hering T, Lewin T, et al. Efficacy and safety of ciclesonide in the treatment of 24,037 asthmatic patients in routine medical care. Respir Med 2011;105(2):186-94
   PubMed Web of Science ®Google Scholar
• Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma. Curr Opin Allergy Clin Immunol 2011;11(4):337-44
   PubMed Web of Science ®Google Scholar
• Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol 1986;21(2):125-9
   PubMed Web of Science ®Google Scholar
• Joshi N, Rajeshwari K. Deflazacort. J Postgrad Med 2009;55(4):296-300
   PubMed Web of Science ®Google Scholar
• Mollmann H, Hochhaus G, Rohatagi S, et al. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 1995;12(7):1096-100
   PubMed Web of Science ®Google Scholar
• Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996;277(1):105-12
   PubMed Web of Science ®Google Scholar
• Teo YL, Saetaew M, Chanthawong S, et al. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012;133(2):703-11
   PubMed Web of Science ®Google Scholar
• Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011;51(12):1712-20
   PubMed Web of Science ®Google Scholar
• Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos 2006;34(6):1035-40
   PubMed Web of Science ®Google Scholar
• Hoover WC, Britton LJ, Gardner J, et al. Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. Ann Pharmacother 2011;45(7-8):e38
   PubMedGoogle Scholar
• Mahlab-Guri K, Asher I, Gradstein S, et al. Inhaled fluticasone causes iatrogenic cushing's syndrome in patients treated with Ritonavir. J Asthma 2011;48(8):860-3
   PubMed Web of Science ®Google Scholar
• Kempsford R, Allen A, Bal J, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol 2013;75(6):1478-87
   PubMed Web of Science ®Google Scholar
• Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr 2013;162(6):1222-7; e2
   PubMed Web of Science ®Google Scholar
• Bjorkhem-Bergman L, Backstrom T, Nylen H, et al. Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Peng CC, Templeton I, Thummel KE, et al. Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2011;89(6):888-95
   PubMed Web of Science ®Google Scholar
• Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64(4):363-8
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002;71(3):196-204
   PubMed Web of Science ®Google Scholar
• Klein K, Zanger UM. Pharmacogenomics of Cytochrome P450 3A4: recent Progress Toward the “Missing Heritability” Problem. Front Genet 2013;4:12
   PubMedGoogle Scholar
• P450. Drug Interaction Table. 2013. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspx [Last accessed 31 May 2013]
   Google Scholar
• Fausnight TB, Craig TJ. Mometasone furoate dry powder inhaler for the treatment of asthma. Expert Opin Pharmacother 2011;12(17):2707-12
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004;60(4):265-8
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006;34(2):225-33
   PubMed Web of Science ®Google Scholar
• Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM. Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. Ann Pharmacother 2007;41(7):1306-9
   PubMed Web of Science ®Google Scholar
• Diederich S, Eigendorff E, Burkhardt P, et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002;87(12):5695-701
   PubMed Web of Science ®Google Scholar
• Langhoff E, Madsen S, Olgaard K, Ladefoged J. Clinical results and cyclosporine effect on prednisolone metabolism of cadaver kidney transplanted patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:963-8
   PubMedGoogle Scholar
• Argenti D, Jensen BK, Hensel R, et al. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J Clin Pharmacol 2000;40(7):770-80
   PubMed Web of Science ®Google Scholar
• Leucker TM, Singh S, Moffett BK. Fluoxetine inhibition of CYP3A4 potentiating adrenal suppression and peptic ulcer disease from intra-articular triamcinolone injections. Pain Med 2013;14(6):952-3
   PubMed Web of Science ®Google Scholar
• Hagan JB, Erickson D, Singh RJ. Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med 2010;11(7):1132-5
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64(3):450-504
   PubMed Web of Science ®Google Scholar
• Rosenborg J, Larsson P, Tegner K, Hallstrom G. Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos 1999;27(10):1104-16
   PubMed Web of Science ®Google Scholar
• Somers GI, Lindsay N, Lowdon BM, et al. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos 2007;35(10):1797-805
   PubMed Web of Science ®Google Scholar
• Brittain RT, Farmer JB, Marshall RJ. Some observations on the -adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol 1973;48(1):144-7
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Paull JD, Richmond BH, et al. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986;22(5):587-93
   PubMed Web of Science ®Google Scholar
• Reszka KJ, Sallans L, Macha S, et al. Airway peroxidases catalyze nitration of the 2{beta}2-agonist salbutamol and decrease its pharmacological activity. J Pharmacol Exp Ther 2011;336(2):440-9
   PubMed Web of Science ®Google Scholar
• Ko K, Kurogi K, Davidson G, et al. Sulfation of ractopamine and salbutamol by the human cytosolic sulfotransferases. J Biochem 2012;152(3):275-83
   PubMed Web of Science ®Google Scholar
• Dominguez-Romero JC, Garcia-Reyes JF, Martinez-Romero R, et al. Detection of main urinary metabolites of beta2-agonists clenbuterol, salbutamol and terbutaline by liquid chromatography high resolution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;923-924:128-35
   PubMed Web of Science ®Google Scholar
• Srichana T, Suedee R, Tanmanee N, et al. The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation. Pulm Pharmacol Ther 2007;20(1):36-45
   PubMed Web of Science ®Google Scholar
• Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 2002;41(1):19-30
   PubMed Web of Science ®Google Scholar
• Manchee GR, Eddershaw PJ, Ranshaw LE, et al. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 1996;24(5):555-9
   PubMed Web of Science ®Google Scholar
• Orlovius AK, Guddat S, Parr MK, et al. Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESI-MS/MS. Drug Test Anal 2009;1(11-12):568-75
   PubMed Web of Science ®Google Scholar
• Meurs H, Oenema TA, Kistemaker LE, Gosens R. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol 2013;13(3):316-23
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-6S
   PubMed Web of Science ®Google Scholar
• Turck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004;44(2):163-72
   PubMed Web of Science ®Google Scholar
• Neale MG, Brown K, Hodder RW, Auty RM. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol 1986;22(4):373-82
   PubMed Web of Science ®Google Scholar
• Agundez JA, Garcia-Martin E, Alonso-Navarro H, Jimenez-Jimenez FJ. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 2013;9(7):859-74
   PubMed Web of Science ®Google Scholar
• Neale MG, Brown K, Foulds RA, et al. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br J Clin Pharmacol 1987;24(4):493-501
   PubMed Web of Science ®Google Scholar
• Balani SK, Xu X, Pratha V, et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 1997;25(11):1282-7
   PubMed Web of Science ®Google Scholar
• Chiba M, Xu X, Nishime JA, et al. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 1997;25(9):1022-31
   PubMed Web of Science ®Google Scholar
• Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007;17(3):189-96
   PubMed Web of Science ®Google Scholar
• Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol 2012;73(2):257-67
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos 2011;39(5):904-11
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, et al. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 2005;33(3):413-18
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009;68(1):61-76
   PubMed Web of Science ®Google Scholar
• 1000_Genomes. A deep catalog of human genetic variation. 2013. Available from: http://browser.1000genomes.org/index.html [Last accessed 31 May 2013]
   Google Scholar
• CYP. The human Cytochrome P450 (CYP) allele nomenclature database. 2013. Available from: http://www.cypalleles.ki.se/ [ Last accessed 31 May 2103]
   Google Scholar
• Blanco G, Martinez C, Ladero JM, et al. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet Genomics 2008;18(1):37-43
   PubMed Web of Science ®Google Scholar
• Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009;5(6):607-20
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Pizarro RM, Martinez C, et al. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 2006;7(4):575-85
   PubMed Web of Science ®Google Scholar
• Ledesma MC, Agundez JA. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 2005;51(6):939-43
   PubMed Web of Science ®Google Scholar
• Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92(2):903-10
   PubMed Web of Science ®Google Scholar
• Palermo M, Marazzi MG, Hughes BA, et al. Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. Steroids 2008;73(4):417-23
   PubMed Web of Science ®Google Scholar
• Shabir I, Marumudi E, Khurana ML, Khadgawat R. Novel mutation of SRD5A2 gene in a patient with 5alpha-reductase 2 deficiency from India. BMJ Case Rep 2012;2012, pii: bcr2012007060. doi: 10.1136/bcr-2012-007060
   Google Scholar
• Redler S, Tazi-Ahnini R, Drichel D, et al. Selected variants of the steroid-5-alpha-reductase isoforms SRD5A1 and SRD5A2 and the sex steroid hormone receptors ESR1, ESR2 and PGR: no association with female pattern hair loss identified. Exp Dermatol 2012;21(5):390-3
   PubMed Web of Science ®Google Scholar
• Han Y, Staab-Weijnitz CA, Xiong G, Maser E. Identification of microRNAs as a potential novel regulatory mechanism in HSD11B1 expression. J Steroid Biochem Mol Biol 2013;133:129-39
   PubMed Web of Science ®Google Scholar
• Barbaro M, Cicognani A, Balsamo A, et al. Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis. Clin Genet 2008;73(5):453-64
   PubMed Web of Science ®Google Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34(13):4202-10
   PubMed Web of Science ®Google Scholar
• CPIC. Clinical Pharmacogenetics Implementation Consortium. 2013. Available from: http://www.pharmgkb.org/page/cpic [Last accessed 31 May 2013]
   Google Scholar